U.S. Surgical Snare Market Size, Share & Forecast 2026–2032

ID: MR-11477 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Surgical Snare Market
  • ✓Market Size 2024: USD 310 million
  • ✓Market Size 2032: USD 520 million
  • ✓CAGR: 6.7%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Ambulatory centers reshaping demand: Colonoscopy with snare removal (CPT 45385) keeps migrating toward freestanding ambulatory surgery centers, where Medicare's ASC payment list supports lower-cost procedure delivery. Those facilities standardise on single-use snares distributed through Owens & Minor and Medline, eroding reusable inventory budgets.
FINDING 02
Reusable snares retaining hospitals: Consensus holds single-use snares will displace reusable instruments. Hospital systems facing rising disposable costs and sustainability pressure from Health Care Without Harm are re-tendering for reusable snares validated for reprocessing, slowing single-use penetration in hospital outpatient departments.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure GPO access early: Foreign manufacturers entering U.S. snare supply should file 510(k) submissions for cold and hot variants by Q3 2026, then secure Premier and Vizient group purchasing contracts before 2027. Pricing access depends on GPO contracts locking in volume.

U.S. Surgical Snares: Market Overview

U.S. surgical snares differ from the global market because demand is anchored in one dominant procedure, colonoscopy polypectomy, and in a reimbursement system that pays per procedure. The market generated an estimated USD 310 million in 2024, roughly a quarter of worldwide snare revenue. Purchasing runs through hospitals, ambulatory surgery centers and gastroenterology practices rather than the public tenders that define much of European demand.

Single-use devices account for the large majority of U.S. units, so the market behaves like a consumables business rather than a capital equipment cycle. Revenue tracks endoscopy procedure volume, which makes unit pricing and procedure mix more important than hardware replacement. Monofilament snares remain the workhorse for standard polyps, while cold snares are gaining share for diminutive lesions under 10 mm as endoscopists adopt resection techniques recommended by the American Society for Gastrointestinal Endoscopy.

Growth Drivers in U.S. Surgical Snares

The first driver is screening expansion. The U.S. Preventive Services Task Force lowered the recommended colorectal cancer screening start age to 45 in 2021, and Section 2713 of the Public Health Service Act requires private insurers to cover recommended screening without cost-sharing, pulling roughly 20 million additional adults into the screening pool. Each positive finding is a candidate for snare polypectomy, so colonoscopy volume converts directly into device demand.

The second driver is demographic and site-of-care migration. Adults aged 65 and older number roughly 61 million, and Medicare beneficiaries carry the highest polyp burden, while CMS has kept gastrointestinal endoscopy on the ASC covered procedures list. The third driver is the shift to single-use devices in infection-control protocols, where hospitals adopt disposable snares to reduce reprocessing liability and staff time.

Market Restraints and Entry Barriers

Regulatory timelines and trade costs raise the entry bar. Snares are cleared through FDA's 510(k) pathway under 21 CFR 876.4300, and the Quality Management System Regulation, which aligns 21 CFR Part 820 with ISO 13485:2016 from February 2, 2026, requires manufacturers to re-verify design controls. Section 301 tariffs on many China-origin medical devices add cost pressure for low-priced snares sourced from Asian contract manufacturers.

Incumbent bundling and purchasing power constrain new entrants. Olympus and Boston Scientific sell snares alongside endoscopes and processors, and Premier and Vizient group purchasing agreements typically lock hospital volume for multi-year terms. Entrants without a bundled capital relationship must negotiate price concessions against established contracts, while ASC buyers apply constant pressure on per-unit disposable costs.

Market Opportunities in U.S. Surgical Snares

Freestanding ASCs represent the most accessible near-term opportunity. More than 5,000 Medicare-certified ASCs perform endoscopy, and many gastroenterology-focused facilities buy snares through distributors rather than negotiated GPO agreements, lowering the contracting barrier. Addressable U.S. colonoscopy volume is estimated near 15 million procedures annually, and entrants offering cold-snare kits for diminutive polyps can target an estimated USD 95 million segment within ASC channels.

Bronchoscopy and urology provide adjacent openings. Snare-based retrieval in these specialties remains under-penetrated relative to colonoscopy, and specialty kits for these channels can be sold without displacing existing gastroenterology contracts. Entrants that complete GUDID registration and UDI-compliant labelling by 2027 will access hospital systems expanding their endoscopy standardisation programmes.

Market at a Glance

IndicatorDetail
Market Size 2024USD 310 million
Market Size 2032USD 520 million
Growth Rate (CAGR)6.7%
Most Critical Decision FactorSecuring GPO contract access and 510(k) clearance timing
Largest RegionSouth Census Region
Competitive StructureConsolidated, with top three suppliers holding a majority of unit share

Leading Market Participants

  • Boston Scientific
  • Olympus Corporation of the Americas
  • Cook Medical
  • Medtronic
  • Micro-Tech Endoscopy
  • Ambu
  • ERBE USA
  • Medi-Globe
  • Conmed
  • Ethicon

Regulatory and Policy Environment

The FDA classifies endoscopic snares as Class II devices, with most cleared through 510(k) under 21 CFR 876.4300. The Medical Device User Fee Amendments (MDUFA V) set the standard FY2025 510(k) fee at USD 24,335, and FDA's review goal is 90 FDA days, although total clearance time often extends to six to nine months once holds are included. The Unique Device Identification rule under 21 CFR Part 830 requires GUDID submission and labelling for each device SKU.

CMS governs reimbursement through the Medicare Physician Fee Schedule, where CPT 45385 covers colonoscopy with snare removal, and through the ASC Covered Procedures List, updated annually in the Federal Register after a 60-day comment period. The Office of the U.S. Trade Representative administers Section 301 duties on China-origin devices, while the HHS Office of Inspector General enforces the Anti-Kickback Statute against distributor rebates and free-goods programmes.

Long-Term Outlook for U.S. Surgical Snares

By 2032 the U.S. surgical snare market will reach USD 520 million at a 6.7% CAGR. Growth will concentrate in ASCs and office-based gastroenterology, where single-use cold and hot snares increasingly form standardised procedure trays.

Competitive intensity will rise as lower-priced Asian manufacturers such as Micro-Tech Endoscopy expand U.S. distribution, pressuring mid-tier suppliers. Boston Scientific and Olympus will defend hospital contracts through endoscope bundling, while independent distributors will capture ASC accounts that lack GPO affiliation.

Frequently Asked Questions

Partnering with an established U.S. distributor for ASC accounts allows faster revenue while 510(k) clearance is pending. Hospital access requires separate GPO contracts with Premier and Vizient.
FDA's review goal is 90 FDA days, but total clearance often runs six to nine months once additional information requests are included. Manufacturers should begin pre-submission meetings early to reduce hold cycles.
Many China-origin medical devices remain subject to Section 301 duties, so importers must confirm HTS classification before shipment. Customs counsel review is advisable for any low-priced product line.
Premier and Vizient group purchasing agreements control a large share of hospital disposable spend. Entrants without GPO listings typically depend on distributor channels for hospital access.
CPT 45385 covers colonoscopy with removal of lesions by snare technique under Medicare's physician fee schedule. Reimbursement levels differ between hospital outpatient departments and ASCs, which shapes site-of-care pricing.

Market Segmentation

By Application
  • Colorectal Polypectomy
  • Upper Gastrointestinal Resection
  • Bronchoscopic Retrieval
  • Urological Retrieval
  • Others
By End User
  • Hospitals
  • Ambulatory Surgery Centers
  • Gastroenterology Practices
  • Academic Medical Centers
  • Others
By Distribution Channel
  • Direct Hospital Sales
  • Independent Distributors
  • Group Purchasing Organizations
  • Online Medical Supply Platforms

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Surgical Snare Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 By Application Insights
4.1 Colorectal Polypectomy
4.2 Upper Gastrointestinal Resection
4.3 Bronchoscopic Retrieval
4.4 Urological Retrieval
4.5 Others
Chapter 05 By End User Insights
5.1 Hospitals
5.2 Ambulatory Surgery Centers
5.3 Gastroenterology Practices
5.4 Academic Medical Centers
5.5 Others
Chapter 06 By Distribution Channel Insights
6.1 Direct Hospital Sales
6.2 Independent Distributors
6.3 Group Purchasing Organizations
6.4 Online Medical Supply Platforms
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Boston Scientific
7.2.2 Olympus Corporation of the Americas
7.2.3 Cook Medical
7.2.4 Medtronic
7.2.5 Micro-Tech Endoscopy
7.2.6 Ambu
7.2.7 ERBE USA
7.2.8 Medi-Globe
7.2.9 Conmed
7.2.10 Ethicon
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.